{
    "2020-08-16": [
        [
            {
                "time": "",
                "original_text": "【华西医药崔文亮团队】《沃森生物点评报告：13价肺炎疫苗放量，mRNA新冠疫苗研发推进》",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "13价肺炎疫苗",
                        "mRNA新冠疫苗",
                        "研发推进"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "增收不增利！沃森生物2020年上半年盈利同比跌27.60% 盈利能力下降",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "盈利能力",
                        "同比下降",
                        "增收不增利"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}